Elvitegravir
- Generic Name
- Elvitegravir
- Brand Names
- Genvoya, Stribild
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23ClFNO5
- CAS Number
- 697761-98-1
- Unique Ingredient Identifier
- 4GDQ854U53
- Background
Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the HIV-1 provirus and resulting propagation of the viral infection. Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug.
Elvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. On September 24, 2014, the FDA approved the single pill form of elvitegravir.
- Indication
Elvitegravir in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) is indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination
- Conditions
- Healthy
- Interventions
- Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDCOther: High-fat BreakfastDrug: Emtricitabine/Tenofovir alafenamide (FTC/TAF)Other: Standardized Regular Breakfast
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 72
- Registration Number
- NCT02475135
Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)
- Conditions
- HIV-1 Infection
- Interventions
- Drug: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitorDrug: Baseline regimen of a non-nucleoside reverse transcriptase inhibitorDrug: Baseline regimen of two nucleoside reverse transcriptase inhibitors
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 673
- Registration Number
- NCT02397096
SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- St Stephens Aids Trust
- Target Recruit Count
- 17
- Registration Number
- NCT02219217
- Locations
- 🇬🇧
St Stephen's AIDS Trust, London, United Kingdom
Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants
- Conditions
- Acquired Immune Deficiency Syndrome (AIDS)HIV Infections
- Interventions
- Drug: Background regimen
- First Posted Date
- 2013-08-15
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 31
- Registration Number
- NCT01923311
- Locations
- 🇿🇦
Be Part Yoluntu Centre, Cape Town, South Africa
🇮🇹Universita degli Studi di Pavia - Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
🇺🇬Joint Clinical Research Centre, Kampala, Uganda
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
- Conditions
- HIV Infection
- Interventions
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 724
- Registration Number
- NCT00708162
- Locations
- 🇺🇸
Whitman-Walker Clinic, Washington, District of Columbia, United States
🇺🇸Orlando Immunology Center, Orlando, Florida, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 192
- Registration Number
- NCT00445146
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.